Dr Reddy's Laboratories Shares Outstanding 2006-2018 | RDY

Dr Reddy's Laboratories shares outstanding history from 2006 to 2018. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Dr Reddy's Laboratories shares outstanding for the quarter ending September 30, 2018 were 0.166B, a 0.1% increase year-over-year.
  • Dr Reddy's Laboratories 2018 shares outstanding were 0.166B, a 0.49% decline from 2017.
  • Dr Reddy's Laboratories 2017 shares outstanding were 0.167B, a 2.38% decline from 2016.
  • Dr Reddy's Laboratories 2016 shares outstanding were 0.171B, a 0.45% increase from 2015.
Dr Reddy's Laboratories Annual Shares Outstanding
(Millions of Shares)
2018 166
2017 167
2016 171
2015 170
2014 171
2013 171
2012 176
2011 165
2010 240
2009 170
2008 169
2007 159
2006 77
2005 153
Dr Reddy's Laboratories Quarterly Shares Outstanding
(Millions of Shares)
Q2 2018 166
Q1 2018 168
Q4 2018 166
Q3 2017 166
Q2 2017 166
Q1 2017 150
Q4 2017 167
Q3 2016 166
Q2 2016 166
Q1 2016 173
Q4 2016 171
Q3 2015 171
Q2 2015 171
Q1 2015 169
Q4 2015 169
Q3 2014 172
Q2 2014 172
Q1 2014 170
Q4 2014 170
Q3 2013 169
Q2 2013 169
Q1 2013 153
Q4 2013 175
Q3 2012 173
Q2 2012 154
Q1 2012 150
Q4 2012 170
Q3 2011 162
Q2 2011 158
Q1 2011 169
Q4 2011 188
Q3 2010 153
Q2 2010 160
Q1 2010 150
Q4 2010 185
Q3 2009 160
Q2 2009 150
Q1 2009 169
Q4 2009 175
Q3 2008 200
Q2 2008 169
Q1 2008 163
Q4 2008 173
Q3 2007 162
Q2 2007 168
Q1 2007 167
Q4 2007 0
Q3 2006 156
Q2 2006 154
Q1 2006 150
Q4 2006 0
Q3 2005 153
Q2 2005 153
Q1 2005 160
Q4 2005 150
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $5.791B $2.204B
Doctor Reddy's is an emerging global pharmaceutical company with proven research capabilities. They are vertically integrated with a presence across the pharmaceutical value chain. They produce finished dosage forms, active pharmaceutical ingredients and biotechnology products and market them globally, with focus on India, US, Europe and Russia. They conduct research in the areas of cancer, diabetes, cardiovascular, inflammation and bacterial infection
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $53.085B 9.11
Teva Pharmaceutical Industries (TEVA) Israel $22.626B 6.93
Mylan (MYL) United Kingdom $18.006B 7.41
Bausch Health Cos (BHC) Canada $8.859B 6.41
Mallinckrodt Public Limited Company (MNK) United Kingdom $2.571B 4.29
Supernus Pharmaceuticals (SUPN) United States $2.296B 21.75
Amphastar Pharmaceuticals (AMPH) United States $0.953B 103.35
Akorn (AKRX) United States $0.860B 0.00
Homology Medicines (FIXX) United States $0.769B 0.00
Assembly Biosciences (ASMB) United States $0.628B 0.00
CymaBay Therapeutics (CBAY) United States $0.574B 0.00
Corium (CORI) United States $0.459B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.455B 0.00
Voyager Therapeutics (VYGR) United States $0.405B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.296B 0.00
Teligent (TLGT) United States $0.137B 0.00
Sol-Gel Technologies (SLGL) Israel $0.132B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.093B 0.00
Aevi Genomic Medicine (GNMX) United States $0.071B 0.00
Acasti Pharma (ACST) Canada $0.057B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.051B 0.00
Evoke Pharma (EVOK) United States $0.042B 0.00
Agile Therapeutics (AGRX) United States $0.029B 0.00
China Pharma Holdings (CPHI) China $0.014B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.008B 0.00